ClinicalTrials.gov recorded primary completion on 9 August 2026 for a completed Phase 3 study of bimekizumab in people with active axial spondyloarthritis. The study enrolled 508 participants and evaluated the drug’s long-term safety, tolerability, and efficacy across ankylosing spondylitis and nonradiographic axial spondyloarthritis.
Background
The trial addressed active axial spondyloarthritis, a condition that includes radiographic axial spondyloarthritis and ankylosing spondylitis, as well as nonradiographic axial spondyloarthritis. The study record described its purpose as evaluating the long-term safety, tolerability, and efficacy of bimekizumab in these patient groups.
Trial design
This Phase 3 study, identified as NCT04436640, was listed as completed and enrolled 508 participants. Its conditions were axial spondyloarthritis, ankylosing spondylitis, radiographic axial spondyloarthritis, and nonradiographic axial spondyloarthritis. The listed intervention was bimekizumab.
The registry record characterized the study as a long-term assessment. However, the supplied data did not include primary-outcome entries, outcome measurements, statistical analyses, comparator arms, or dosing information.
What this means
The primary-completion event confirms that the Phase 3 study reached the completion stage for its planned evaluation of bimekizumab in active axial spondyloarthritis. The available record does not provide numerical efficacy findings, safety-event totals, p-values, confidence intervals, or comparative results. As a result, the supplied data support reporting the study’s completion and scope, but not a conclusion about treatment benefit or comparative safety.
Source
Source: ClinicalTrials.gov, registry record for the completed Phase 3 long-term safety, tolerability, and efficacy study of bimekizumab in active axial spondyloarthritis, dated 9 August 2026. Available at clinicaltrials.gov/study/NCT04436640.